La cadena de opciones muestra datos clave de las opciones de acciones de BioAtla a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para BioAtla..

BioAtla (NASDAQ:BCAB) Bolsa, Cadena de Opciones

BioAtla

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

BioAtla Inc

Morningstar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORN#NASDAQ">MORN</a>) has outperformed the market over the past 15 years by 26.44% on an annualized basis producing an average annual return of 37.38%. Currently, Morningstar has a market capitalization of $12.20 billion. 
Buying $100 In MORN: If an investor had bought $100 of MORN stock 15 years ago, it would be worth $11,694.77 today based on a price of $284.43 for MORN at the time of writing.
<h3>Morningstar's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741793411_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

MORN

Here's How Much $100 Invested In Morningstar 15 Years Ago Would Be Worth Today

DOR/ISL demonstrated non-inferiority and a similar safety profile to comparator antiretroviral therapies in adults with virologically suppressed HIV-1
Merck (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), known as MSD outside of the United States and Canada, today announced the presentation of positive results from two pivotal Phase 3 trials of the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100mg/0.25mg)] in adults with HIV-1 infection that is virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamidei [BIC/FTC/TAF (50mg/200mg/25mg)] in trial <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05630755&amp;esheet=54223136&amp;newsitemid=20250312706063&amp;lan=en-US&amp;anchor=MK-8591A-052&amp;index=1&amp;md5=d962319798a591d93c498e4e23a89f2f">MK-8591A-052</a>) or antiretroviral therapy [baseline antiretroviral therapy (bART)] in trial <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05631093%3Fterm%3Dislatravir%26page%3D2%26rank%3D20&amp;esheet=54223136&amp;newsitemid=20250312706063&amp;lan=en-US&amp;anchor=MK-8591A-051&amp;index=2&amp;md5=9f12d7e4233e638166ba99975cc400aa">MK-8591A-051</a>. In both trials, DOR/ISL met the primary efficacy success criterion for non-inferiority to comparator antiretroviral therapies and primary safety objectives at Week 48. The findings will be shared in late-breaking oral presentations at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI) being held in San Francisco and were featured in a CROI press conference. Merck plans to begin submitting applications for marketing authorization to regulatory agencies by mid-2025.
In the double-blind trial MK-8591A-052 (Abstract #204A), results for the primary endpoint (HIV-1 RNA ≥50 copies/mL) showed that 1.5% of participants who switched to DOR/ISL had a viral load of ≥50 copies/mL at Week 48, compared to 0.6% on BIC/FTC/TAF (treatment difference 0.9%, 95% CI -1.9, 2.9). At Week 48, 91.5% of participants who switched to DOR/ISL maintained viral suppression (HIV-1 RNA &lt;50 copies/mL) compared to 94.2% of participants who continued receiving BIC/FTC/TAF (treatment difference -2.6%, 95% CI -7.1, 2.6; secondary endpoint).
In the open-label trial MK-8591A-051 (Abstract #204B), results for the primary endpoint (HIV-1 RNA ≥50 copies/mL) showed that 1.4% of participants who received DOR/ISL had a viral load of ≥50 copies/mL at Week 48, compared to 4.9% on bART (treatment difference -3.6%, 95% CI -7.8, -0.8. At Week 48, 95.6% of participants who switched to DOR/ISL maintained viral suppression (HIV-1 RNA &lt;50 copies/mL) compared to 91.9% of participants who continued on bART (treatment difference 3.7%, 95% CI -0.3, 8.9; secondary endpoint).
Across both trials, the safety profile of DOR/ISL was generally comparable to the comparator antiretroviral regimens, including BIC/FTC/TAF in MK-8591A-052. At Week 48, the mean percent change in total lymphocyte and CD4 counts were similar for DOR/ISL and comparator regimens. No treatment-emergent resistance to DOR or ISL was observed in either trial.

Biotech

General

Merck Announces Data From Phase 3 Trials That Show The Investigational, Once-Daily, Oral, Two-Drug Regimen Of Doravirine/Islatravir Maintained HIV-1 Viral Suppression At Week 48

Wells Fargo analyst Sam Reid maintains Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) with a Overweight and lowers the price target from $205 to $180.

Price Target

Analyst Ratings

FERG

Wells Fargo Maintains Overweight on Ferguson Enterprises, Lowers Price Target to $180

Wells Fargo analyst Yanan Zhu maintains Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) with a Overweight and lowers the price target from $12 to $10.

VYGR

Wells Fargo Maintains Overweight on Voyager Therapeutics, Lowers Price Target to $10

Wells Fargo analyst Roger Read maintains Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) with a Overweight and lowers the price target from $219 to $215.

FANG

Wells Fargo Maintains Overweight on Diamondback Energy, Lowers Price Target to $215

Barclays analyst Brandt Montour maintains Viking Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) with a Equal-Weight and lowers the price target from $49 to $46.

Barclays Maintains Equal-Weight on Viking Holdings, Lowers Price Target to $46

Barclays analyst Brandon Oglenski maintains United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) with a Overweight and lowers the price target from $150 to $140.

Barclays Maintains Overweight on United Airlines Holdings, Lowers Price Target to $140

February's Consumer Price Index report released Wednesday came in cooler-than-expected and bolstered Wall Street's expectations for rate cuts in the months ahead. Here's a look at economists' reactions to <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44275575/wall-street-rockets-as-february-inflation-cools-more-than-expected">the latest inflation data.&nbsp;&nbsp;</a>
What To Know: Headline inflation eased slightly to 2.8% year-over-year, and core CPI, which strips out food and energy prices, slowed to 3.1%. Following the inflation print, traders fully priced in three Federal Reserve rate cuts in 2025, according to the CME FedWatch Tool.
Read Next: <a href="https://www.benzinga.com/25/03/44277920/mortgage-applications-soar-as-rates-hit-lowest-level-since-october">Mortgage Applications Soar As Rates Hit Lowest Level Since October</a>
Expert Ideas: Bill Adams, chief economist for Comerica Bank, said that inflation is moving in the "right direction," making it more likely that the Fed will cut rates. Comerica forecasts a single 0.25% interest rate cut in 2025, likely occurring in July.
However, the Fed forecast is hazy given the uncertainty surrounding future Trump administration policies.&nbsp;
"The range of outcomes feels wider than usual given the unpredictability of the policies affecting prices and the job market," Adams said.&nbsp;
Chris Zaccarelli, chief investment officer for Northlight Asset Management, also highlighted the increased economic and geopolitical uncertainty and pointed to the lower rate of inflation, which allows the Fed to support a struggling economy with rate cuts if needed.
"If all of these policy changes lead to a weaker dollar, an increase in geopolitical uncertainty, and a loss of the exorbitant privilege of having the world&#8217;s reserve currency, then many of the lessons that investors have learned over the previous eight decades will need to be forgotten," Zaccarelli warned.&nbsp;
While markets were relieved with the cool inflation report on Wednesday, price increases following the pandemic have added up over the past five years. Charlie Bilello, chief market strategist for Creative Planning, featured a list on social media showing U.S. home prices up 52.3% and auto insurance 55.4% higher.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Price Increases over last 5 years&#8230; CPI Medical Care: +12.3% CPI New Cars: +20.3% CPI Shelter: +26.6% CPI Food at home: +27.4% CPI Gasoline: +27.6% CPI Food away from home: +30.1% CPI Electricity: +32.7% CPI Used Cars: +35.1% CPI Transportation: +36.2% CPI Fuel Oil: +41.9% CPI…
&mdash; Charlie Bilello (@charliebilello) <a href="https://twitter.com/charliebilello/status/1899809167025516658?ref_src=twsrc%5Etfw">March 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Market Reactions: U.S. markets were mixed in late morning trading with the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), tracking the S&amp;P 500, flat at $555.92 and the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), tracking the Nasdaq 100, up 0.47% at $473.81.&nbsp;
The benchmark 10-year yield rose slightly to 4.29%. The SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), tracking the price of gold, rose 0.17% to $269.61.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/44015237/pending-home-sales-crash-to-record-low-jobless-claims-soar-wall-street-reacts">Pending Home Sales Crash To Record Low, Jobless Claims Soar: Wall Street Reacts</a></li>
</ul>
Image: Shutterstock

Inflation Moves In The 'Right Direction' But Forecast Is Hazy, Economist Says

Oppenheimer analyst Scott Schneeberger maintains Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) with a Outperform and lowers the price target from $234 to $189.

Oppenheimer Maintains Outperform on Ferguson Enterprises, Lowers Price Target to $189

Barclays analyst Brendan Lynch maintains Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) with a Overweight and lowers the price target from $361 to $354.

Barclays Maintains Overweight on Public Storage, Lowers Price Target to $354

Citizens Capital Markets analyst Jason Butler maintains Zevra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) with a Market Outperform and raises the price target from $17 to $18.

ZVRA

Citizens Capital Markets Maintains Market Outperform on Zevra Therapeutics, Raises Price Target to $18

Barclays analyst Brendan Lynch maintains National Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSA#NYSE">NSA</a>) with a Equal-Weight and lowers the price target from $42 to $41.

Barclays Maintains Equal-Weight on National Storage, Lowers Price Target to $41

Synovus Finl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) short percent of float has risen 10.0% since its last report. The company recently reported that it has 4.27 million shares sold short, which is 3.41% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.92 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Synovus Finl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741792530_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Synovus Finl has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Synovus Finl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Synovus Finl's peer group average for short interest as a percentage of float is 3.72%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Synovus Finl?

AST SpaceMobile's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NYSE">ASTS</a>) short percent of float has risen 6.73% since its last report. The company recently reported that it has 45.28 million shares sold short, which is 23.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.69 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>AST SpaceMobile Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741792524_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AST SpaceMobile has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing AST SpaceMobile's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, AST SpaceMobile's peer group average for short interest as a percentage of float is 5.19%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ASTS

Is the Market Bullish or Bearish on AST SpaceMobile?

RB Global's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBA#NYSE">RBA</a>) short percent of float has fallen 33.16% since its last report. The company recently reported that it has 4.03 million shares sold short, which is 2.5% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.61 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>RB Global Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741792520_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for RB Global has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing RB Global's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, RB Global's peer group average for short interest as a percentage of float is 5.33%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into RB Global's Recent Short Interest

Global Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) has outperformed the market over the past 20 years by 1.46% on an annualized basis producing an average annual return of 9.51%. Currently, Global Payments has a market capitalization of $23.39 billion. 
Buying $100 In GPN: If an investor had bought $100 of GPN stock 20 years ago, it would be worth $621.50 today based on a price of $94.48 for GPN at the time of writing.
<h3>Global Payments's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741792516_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

Barclays analyst Richard Hightower maintains Invitation Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVH#NYSE">INVH</a>) with a Overweight and raises the price target from $36 to $37.

INVH

Barclays Maintains Overweight on Invitation Homes, Raises Price Target to $37

Citizens Capital Markets analyst Andrew Boone reiterates Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Market Outperform and maintains $115 price target.

Reiteration

Citizens Capital Markets Reiterates Market Outperform on Trade Desk, Maintains $115 Price Target

Barclays analyst Matthew Bouley maintains Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) with a Overweight and lowers the price target from $211 to $190.

Barclays Maintains Overweight on Ferguson Enterprises, Lowers Price Target to $190

The <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42667932/did-vladimir-putin-just-ban-bitcoin-mining-in-russia-the-devil-is-in-the-details">Bank of Russia</a> has proposed allowing a limited group of qualified investors to purchase and sell cryptocurrencies under a new three-year experimental legal regime.
What Happened: Announced on Wednesday in accordance with President Vladimir Putin's directives, the initiative targets "particularly qualified" investors—individuals with over 100 million rubles ($1.02 million) in securities and deposits or annual income exceeding 50 million rubles ($510,000)—and companies already classified as qualified investors.
This <a href="https://cbr.ru/press/event/?id=23448">move</a>, detailed in a submission to the Russian government, contrasts with the country's historical reluctance to adopt Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) as a reserve asset, as reaffirmed by Deputy Finance Minister Vladimir Kolychev.
The Bank of Russia emphasized that cryptocurrencies, lacking issuance or guarantees from any jurisdiction and driven by mathematical algorithms, are subject to significant volatility. 
"Investors, when deciding to invest in cryptocurrencies, must be aware that they are taking on the risks of potential loss of their funds," the bank stated in its proposal. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44275216/bitcoin-to-defy-trump-tariffs-recession-fears-will-hit-200000-by-end-of-2025-standard-chartered">Bitcoin To Defy Trump Tariffs, Recession Fears, Will Hit $200,000 By End Of 2025: Standard Chartered</a>
Why It Matters: This development follows Putin's December 2024 assertion that "nobody can ban Bitcoin," highlighting the decentralized nature of the technology, though his administration has historically prioritized stability over crypto adoption.
In 2021, Putin noted, "Bitcoin has value, but it's too unstable for oil trade," a stance echoed by Kolychev, who last week told Interfax that the National Wealth Fund (NWF), valued at 11.97 trillion rubles ($122.09 billion) as of Feb. 1 will continue favoring gold (40%) and yuan (up to 60%) over Bitcoin due to its volatility.
"From a sovereign budget reserve perspective, it is crucial that the fund's assets are highly liquid and can be quickly sold without significant loss in value," Kolychev said, reinforcing Russia's cautious approach despite its 5.6% GDP allocation falling below the 7-10%<a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44170204/vladimir-putin-said-nobody-can-ban-bitcoin-but-russia-isnt-looking-to-follow-donald-trumps-push-for-a-crypto-reserve"> threshold for riskier assets.</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44273077/bitcoin-is-digital-sound-money-in-the-safest-most-prosperous-time-in-history-anthony-pompliano-says">Bitcoin Is &#8216;Digital Sound Money&#8217; In The Safest, Most Prosperous Time In History, Anthony Pompliano Says</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

After Vladimir Putin Said 'Nobody Can Ban Bitcoin', The Bank Of Russia Is Looking To Allow Crypto Purchases

Health Care

Press Releases

BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024

Earnings

BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Comments

BioAtla

BioAtla (BCAB) Opciones

BioAtla (NASDAQ:BCAB) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL